Effect of Acute ObeEnd Exposure on Factors Regulating Appetite

Last updated: July 2, 2024
Sponsor: Concordia University, Montreal
Overall Status: Active - Recruiting

Phase

N/A

Condition

Obesity

Diabetes Prevention

Treatment

Placebo band

Functional band

Clinical Study ID

NCT06487234
30015229
  • Ages 18-60
  • All Genders

Study Summary

n Canada, over 60% of adults are classified as overweight and obese resulting in a public health crisis including increasing health care costs and negatively impacting the well-being of many Canadians. To overcome these barriers, the ObeEnd device, manufactured by WAT Medical Enterprise, is a new and innovative wellness technology that uses electrical pulses to stimulate acupressure point PC6 to help control appetite. PC6 stimulation could potentially modulate appetite and restore gastric dysfunction, which are important factors that contribute to obesity. If PC6 electrostimulation facilitates the normalization of appetite and restoration of gastric dysfunction in those with obesity, then the device could be a potentially helpful aid to weight loss.

To measure the change of appetite hormones and enzymes related to appetite regulation after using the ObeEnd device. The investigators hypothesize that, compared to placebo, acute electrostimulation of PC6 an acupuncture spot on the wrist for a 1 hour period will result in changes in enterogastric hormones in a direction that decreases appetite. This study will provide the first evidence of the acute effects of electrostimulation at PC6 on factors affecting body weight regulation providing insight into the utility of the ObeEnd device for weight control.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • People with obesity (BMI>30kg/m2)

  • Generally healthy

  • Premenopausal females

Exclusion

Exclusion Criteria:

  • Past (<1 year) or present use of nicotine products

  • History of chronic disease or metabolic conditions

  • Females who are pregnant, less than 6 months postpartum, or breastfeeding

  • Diagnosed hepatic disease, renal impairment, uncontrolled hypothyroidism

  • Use of any medications that may affect study outcomes (e.g. hormone replacementtherapy)

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Placebo band
Phase:
Study Start date:
July 05, 2024
Estimated Completion Date:
April 01, 2025

Connect with a study center

  • Concordia University

    Montreal, Quebec H4B1R6
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.